Elon Musk’s biotech company Neuralink is expanding its operations to Canada and is looking for six patients with quadriplegia to receive its flagship N1 brain implant following Health Canada’s approval of the plans.
The study, dubbed CAN-PRIME, will implant the chips in approved Canadian patients and monitor their health and abilities long-term. The chip is designed to help people who can’t use their hands operate phones and computers using their thoughts. This appears to be virtually identical to Neuralink’s US study in terms of eligibility and purpose of the human testing.
Toronto, Ontario’s University Health Network will conduct the first Canadian Neuralink study. “We are incredibly proud to be at the forefront of this research advancement in neurosurgery,” Dr. Kevin Smith, UHN’s President and CEO, said in a statement. “This progress is a testament to the dedication and expertise of our world-leading medical and research professionals, as well as our commitment to providing the most innovative and effective treatments for patients. As the first and…
